Avid Bioservices Inc (CDMO)

[jakedogman1]

another lottery ticket... i check oncologie website from time to time... this is new to me... the potential value to cdmo is in any milestones for trials ...

https://www.oncologie.international/our-pipeline

Varisacumab is an investigational monoclonal antibody that uniquely blocks the epitope for vascular endothelial growth factor A (VEGFA), binding only to VEGF Receptor 2 (VEGFR2). VEGF is a validated cancer pathway, and new understanding shows the importance of selectivity on the receptor VEGFR2 compared to VEGFR1.

Oncologie acquired Varisacumab from Avid Bioservices, Inc. in October 2018.

on another topic... the persistent shorting as evidenced by the circuit breaker yesterday makes me wonder about a capital placement on the near term horizon... and given the ad for a project engineer, one doesn't hire a full time engineer for a small lab expansion... if there is projected add rev from expansion, the dilution should be offset by discounted value of future revs... and is mgmt really going to bat for shareholders or is this groundhog day with the option grant game.... they reworked the plan last dec per dec filing... hopefully mgmt understands what happened to the last regime when they put their own interests ahead of shareholders...